Jorge Puente

Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA.

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.

Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022.

California Pacific Medical Center operates medical centers. It offers acute and specialty care services including obstetrics, gynecology, cardiovascular, pediatrics, neurosciences, orthopedics, and organ transplantation. The company is headquartered in San Francisco, CA.

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Syneos Health Consulting, Inc. provides consulting services to pharmaceutical and biotech industries. It is organized into practice areas, each specializing in a critical industry function: brand management, business development, clinical development, managed markets, medical affairs, sales, and trade and distribution. The company was founded by John J. Campbell in 1997 and is headquartered in Morrisville, NC.

Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.

Quintiles Capital Solutions (Quintiles Capital) is a venture capital firm founded in 2000. The firm is headquartered in Durham, North Carolina.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

Silk Technologies Ltd. develops silk-derived protein (SDP) products for ophthalmic applications. Its patented SDP material is currently being developed as a compound for the treatment of patients with dry eye disease. The company was founded by Brian D. Lawrence and is headquartered in Plymouth, MN.

Ophthalmology Innovation Summit provides investment services. The private company is based in Jericho. The American company was founded by Emmett T. Cunningham, Gilbert H. Kliman.

3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA.

Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Pr3vent, Inc provides healthcare technology services. The company was founded by Jochen Kumm and Darius M. Moshfegh and is headquartered in Palo Alto, CA.

Adanate, Inc. develops antibody therapeutics. The CEO of the American company is Chris Griffith.

Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.

Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Ifm Therapeutics, Inc. develops immunotherapy that focuses on targeting the adaptive immune system. The private company is based in Boston and was founded by Jean-Francois B. Formela.

Part of Ainsly Ltd., Placid0, Inc. develops a mobile platform for assessing ocular conditions. The company is based in Pasadena, CA. The company was founded in 2020 by Andrew Moshfeghi, Zach Bodnar, Darius M. Moshfeghi, Jochen Kumm, Emmett T. Cunningham. Placid0 was acquired by Ainsly Ltd. on February 10, 2022.